After a long-standing feud, Novo Nordisk and telehealth firm Hims & Hers Health are set to announce a surprising partnership that would allow Novo Nordisk to sell Wegovy through HIMS’ platform. The news, reported by Bloomberg, suggests that the companies are putting their differences aside to collaborate.
Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter…
…
Novo and Hims plan to announce a new partnership as soon as Monday, according to the person, who spoke on the condition of anonymity. The two companies had a similar agreement last year, but Novo abruptly scrapped it after Hims refused to stop marketing and selling copycat medications.
The unexpected development comes after Novo Nordisk recently sued HIMS over a copycat Wegovy pill and patent infringement. Despite this legal battle, both companies seem to have found common ground to work together.
Analyst Michael Cherny from Leerink Partners expressed optimism about the partnership, stating, “There is no other way to describe the Hims news as both a surprise and an unabashed positive for Hims’ stock.” Following the news, Novo Nordisk’s ADRs rose 2% in after-hours trading, while HIMS shares surged nearly 40%.
Cherny also highlighted Novo Nordisk’s strategic move to expand its market reach through partnerships with digital pharmacies like HIMS. The resolution of the feud is expected to benefit both companies and end the ongoing disputes.
With the feud now seemingly resolved, investors are hopeful about the future prospects of both Novo Nordisk and Hims & Hers Health. The details of the partnership and the reasons behind the reconciliation are likely to be revealed by company executives in the coming days.
Novo Nordisk’s decision to collaborate with HIMS signals a shift in strategy as the company aims to navigate the competitive obesity market and address investor concerns about its stock performance. The partnership could be a turning point for both companies as they seek to enhance their market positions.
As Novo Nordisk and Hims & Hers Health embark on this new chapter of collaboration, the healthcare industry awaits further developments and insights into their joint initiatives.
Source: marketdesk.ai